The Decibel
Skinny, Inc. Part 1: The Canadian connection to Ozempic artwork

Skinny, Inc. Part 1: The Canadian connection to Ozempic

The Decibel
32:04
Play episode

Show notes

Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades. Today, he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians. Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s – and a patient who takes them. This episode originally aired February 23, 2026. This is part of a three-part series. You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from this show

More
Now Playing
Skinny, Inc. Part 1: The Canadian connection to Ozempic — The Decibel | Josplay Music